Dr. James T. Boyd, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 300
Licensed in Vermont since 2004, according to the Vermont Board of Medical Practice. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
VT license 0420010882 (first issued 2004; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Univ. of Vermont - Fletcher Allen Health Care Burlington, VT
- Northwestern Medical Center Inc Saint Albans, VT
- Porter Hospital Inc Middlebury, VT
Medical groups
- University of Vermont Medical Center Inc (1,208 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 300
- Services billed
- 1,583
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 229 | 142 |
| Established patient office or other outpatient visit, 40-54 minutes | 114 | 77 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 89 | 33 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 76 | 28 |
| Injection of chemical for paralysis of nerve muscles on side of face | 64 | 20 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 61 | 16 |
| Established patient office or other outpatient visit, 20-29 minutes | 45 | 32 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 44 | 16 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 43 | 26 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 34 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Burlington, VT | 347 |
| Rytary (carbidopa/levodopa) Other prescribers in Burlington, VT | 168 |
| Carbidopa-Levodopa Er (carbidopa/levodopa) Other prescribers in Burlington, VT | 152 |
| Amantadine (amantadine hcl) Other prescribers in Burlington, VT | 145 |
| Clozapine Other prescribers in Burlington, VT | 128 |
| Austedo (deutetrabenazine) Other prescribers in Burlington, VT | 120 |
| Gabapentin Other prescribers in Burlington, VT | 83 |
| Clonazepam Other prescribers in Burlington, VT | 76 |
| Pramipexole Dihydrochloride (pramipexole di-hcl) Other prescribers in Burlington, VT | 75 |
| Rasagiline Mesylate | 71 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $564,485 in research payments for these studies, mostly to the institutions running them.
- Phase II study in early stage Parkinson s Disease Patients
Roche Tcrc, Inc. - A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease
Genentech, Inc. - An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease
UCB SA · Terminated · NCT05543252 - A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
UCB SA · Completed · NCT04658186
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.